Page last updated: 2024-10-30

lansoprazole and Atherogenesis

lansoprazole has been researched along with Atherogenesis in 2 studies

Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Ma, Y1
Li, S1
Yang, H1
Zhang, Y1
Li, H1
Zhou, L1
Lin, J1
Chen, Y1
Hou, Y1
Zhang, X1
Liu, T1
Zhou, X1
Wang, Y1
Aydemir, S1
Eren, H1
Tekin, IO1
Harmandar, FA1
Demircan, N1
Cabuk, M1

Trials

1 trial available for lansoprazole and Atherogenesis

ArticleYear
Helicobacter pylori eradication lowers serum asymmetric dimethylarginine levels.
    Mediators of inflammation, 2010, Volume: 2010

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Arginine; Athero

2010

Other Studies

1 other study available for lansoprazole and Atherogenesis

ArticleYear
Acid suppressants use and risk of atherosclerotic cardiovascular disease in middle-aged and older adults.
    Atherosclerosis, 2022, Volume: 358

    Topics: Aged; Antihypertensive Agents; Atherosclerosis; Cardiovascular Diseases; Histamine; Humans; Lansopra

2022